Omaxe FY26 Results: Financial Stress and Regulatory Hurdles

Revenue: Rs 1,253.40 Crore | Net Loss: Rs 696.80 Crore

Reader Takeaway: Omaxe improved project deliveries by 24% but remains under pressure from rising debt and unresolved SEBI regulatory investigations.

What just happened

Omaxe Limited has released its audited financial results for FY 2025-26, showing a decline in consolidated revenue to Rs 1,253.40 crore compared to Rs 1,560.99 crore in the previous year. The company’s net loss widened slightly to Rs 696.80 crore from Rs 685.40 crore in FY25. A critical area of concern for investors is the sharp rise in total borrowings, which escalated from Rs 743.56 crore to Rs 1,425.17 crore over the fiscal year.

Why this matters

The financial results reflect the challenges inherent in the company’s capital-intensive strategy of focusing on large-scale integrated townships. While Omaxe successfully delivered 5.33 million sq. ft. of space—a 24% year-on-year increase—the bottom line remains deeply negative. The significant accumulation of debt suggests increased pressure on the balance sheet, which stakeholders must monitor closely alongside cash flow requirements for new projects in Amritsar and Indore.

Regulatory and Legal Update

Omaxe is currently navigating two major regulatory files. The company is contesting a July 2024 SEBI order that restrained it and its board from market access; a stay was granted by the SAT, and the final order is currently reserved. Additionally, the company is responding to a January 2026 show-cause notice regarding alleged non-compliance with Minimum Public Shareholding (MPS) norms dating back to FY 2013-14.

What to track next

Investors should look toward the 37th Annual General Meeting scheduled for September 25, 2026. The outcome of the pending SAT proceedings and the adjudication of the MPS norms case will be critical for the stock's future stability and market sentiment.